Why GlaxoSmithKline plc Is Worth More Than 1,700p Per Share

GlaxoSmithKline plc (LON: GSK) is severely undervalued at present levels.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is one of the most undervalued and underappreciated FTSE 100 companies, in my opinion. Glaxo is also difficult to understand.

On the face of it, many investors see the company as one of the UK’s largest pharmaceutical companies, which is struggling to boost sales. However, there’s more to Glaxo than meets the eye.

Indeed, while the company is best known for its big pharma roots, recent management initiatives to increase the group’s presence in the consumer healthcare market have turned Glaxo into a quasi-consumer goods company, with an added income stream from pharmaceutical products. 

Consumer healthcare

Glaxo’s consumer health division is one of the world’s largest consumer health product suppliers, producing a range of over-the-counter medicines and skin treatments. Income from this unit is relatively stable and predictable. The same can be said for Glaxo’s vaccines unit. 

On the other hand, Glaxo’s respiratory business is more unpredictable. Many of Glaxo’s troubles over the past few years can be traced to the group’s respiratory business. 

Last year’s $20bn deal with Novartis will see Glaxo become the world’s leading consumer healthcare company through a joint venture. The deal saw Glaxo dispose of its oncology portfolio for $16bn while acquiring Novartis’ global Vaccines business for $5.3bn.

Glaxo and Novartis are creating a new consumer healthcare joint venture, with 2013 pro forma revenues of £6.5bn. Glaxo will have majority control of this world-leading consumer healthcare business with an equity interest of 63.5% and the option to buy out the remainder after three years.

There’s also plenty of value trapped in the rest of the Glaxo group.

Glaxo’s ViiV Healthcare HIV joint venture with Pfizer could be worth around £7bn and Glaxo holds an equity interest in South Africa’s generic pharmaceutical producer Aspen Pharmacare. On top of these interests, Glaxo has 40 new drugs under development in its treatment pipeline. 

Fire up growth

All of the above factors will fire up Glaxo’s growth over the medium term. Group revenue is expected to grow at a compound annual growth rate of “low-to-mid single digits” over the five years from 2016 to 2020.

Over the same period, core earnings per share are expected to expand at a rate in the “mid-to-high single digits”.

But despite these growth projections, Glaxo’s defensive consumer healthcare business, its treatment pipeline and lucrative joint ventures, Glaxo is the cheapest big pharma group by far.

Cheapest of the pack

Glaxo’s peers, including the likes of Novartis, Pfizer, Roche and Sanofi all trade at an average forward P/E of 21.1. Glaxo trades at an average forward P/E of 18.1. What’s more, based on City earnings estimates for 2016 and 2017, Glaxo is currently trading at a valuation discount of 30% to its wider peer group.

Other valuation metrics also show the same kind of discount. Using the enterprise value to earnings before interest and tax or EV/EBIT metric, Glaxo is trading at a discount of 50% to its wider peer group on both a forward and current basis. These figures indicate that Glaxo should be trading 30% to 50% above current levels, in the region of 1,790p to 2,069p per share. 

To complement this upside, Glaxo currently supports a dividend yield of 5.8% so investors will be paid to wait for the company’s return to growth. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »